
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed |
AstraZeneca PLC reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 11,390 million compared to USD 7,320 million a year ago. Net income was USD 386 million compared to USD 1,561 million a year ago. Basic earnings per share from continuing operations was USD 0.25 compared to USD 1.19 a year ago. Diluted earnings per share from continuing operations was USD 0.25 compared to USD 1.18 a year ago.
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Total Revenue | 8220 | 7320 | 7410 | 6578 |
Gross Profit | 6027 | 5400 | 5895 | 5188 |
Operating Income | 1127 | 1895 | 1487 | 1171 |
Net Income | 550 | 1561 | 1012 | 648 |
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Total Assets | 73641 | 64926 | 66729 | 64112 |
Total Liabilities | 57965 | 50496 | 51107 | 51917 |
Total Equity | 15676 | 14430 | 15622 | 12195 |
Period Ending: | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 2826 | 1934 | 4799 | 3001 |
Cash From Investing Activities | 319 | 555 | -285 | -423 |
Cash From Financing Activities | 4558 | -2731 | -2203 | 7 |
Net Change in Cash | 7651 | -309 | 2323 | 2571 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review